@article{Olaniyi_2011, title={Therapy Outcome of a T-Cell-Rich-B-Cell Lymphoma (TCRBCL) Patient with Rituximab-CHOP in Ibadan, Nigeria: a Case Report.}, volume={3}, url={https://www.mjhid.org/mjhid/article/view/2011.008}, DOI={10.4084/mjhid.2011.008}, abstractNote={<p class="MsoNormal" style="text-align: justify; margin: 0in 0in 0pt;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span style="font-size: small;"><span style="font-family: Times New Roman;">T-cell-rich B-cell lymphoma (TCRBCL) is considered a rare variant of aggressive B cell lymphoma characterized by few neoplastic B cells and a large reactive infiltrate with striking similarities to nodular lymphocyte predominant Hodgkin’s lymphoma.</span></span></span></p><p class="MsoNormal" style="text-align: justify; margin: 0in 0in 0pt;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB">A case of a 46 year old man referred with a </span>5 months history of generalized lymphadenopathy, weight loss, low grade pyrexia and two separately reported lymph node histology consistent with TCRBCL is described.</span></span></p><p class="MsoNormal" style="text-align: justify; margin: 0in 0in 0pt;"><span style="font-size: small;"><span style="font-family: Times New Roman;">The clinical course was indeed aggressive because in spite of initial treatment with four cycles of CHOP combination chemotherapy, followed by Rituximab+CHOP(x 6 cycles), signs of tumor re-growth/infiltration were frequently observed. Also recurrent infection was frequent, troublesome and eventually became overwhelming resulting to the loss of the patient.</span></span></p><p class="MsoNormal" style="text-align: justify; margin: 0in 0in 0pt;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span style="font-size: small;"><span style="font-family: Times New Roman;">This case, being the first case of TCRBCL diagnosed immunohistochemically and managed at this centre with R-CHOP, is presented to highlight the dilemma in making diagnosis (which required meticulous immunohistochemistry), clinical challenges faced and rituximab therapy outcome especially in resource poor country. It will also serve to increase our index of suspicion and the need reinforce immunohistochemistry in the diagnosis of lymphoma.</span></span></span></p><p class="MsoNormal" style="text-align: justify; line-height: 200%; margin: 0in 0in 0pt;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span style="font-family: Times New Roman; font-size: small;"> </span></span></p><p class="MsoNormal" style="text-align: justify; margin: 0in 0in 0pt;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span style="font-size: small;"><span style="font-family: Times New Roman;">Keywords:- T-cell-Rich B-cell Lymphoma, Immunohistochemistry, Rituximab, Recurrent infection</span></span></span></p>}, number={1}, journal={Mediterranean Journal of Hematology and Infectious Diseases}, author={Olaniyi, John Ayodele}, year={2011}, month={Mar.}, pages={e2011008} }